A Breath THC Cutoff Can Be Analytical Without Being an Impairment Threshold

A breath assay’s reporting cutoff does not become an impairment threshold merely because the method accurately measures THC. A Cannabix collection-and-analysis study validated analytical procedures, not a concentration that identifies unsafe driving.

What was calibrated

The procedure collected a specified breath volume onto cartridges and used LC–MS/MS to separate delta-9 THC, delta-8 THC, CBD and cannabinol. Calibrators and quality controls were prepared by adding reference compounds to unused collection pods.

Cartridge calibration establishes the relationship between loaded analyte and laboratory response. It is distinct from proving how efficiently the complete device captures every person’s exhaled cannabinoid across different breathing patterns and conditions.

The human application had naturalistic dosing

Participants smoked their own cannabis ad libitum, with reported product potencies, and provided samples before and after use. Ambient-air collections were included. This demonstrates application to actual breath samples, but does not standardize absorbed dose.

The study’s analytical cutoff, including a 5-pg/L example, should be identified as a method-specific reporting decision. It was not derived by validating the boundary against driving outcomes in this experiment.

Split samples answer a different question

The collection system allows separately sealed primary and confirmatory samples. Preserving material for another analysis is valuable for review and chain of custody. It does not, by itself, validate the inference from a concentration to impairment.

Separate laboratory analysis can investigate identity and concentration while leaving unresolved whether the measured exposure caused a particular functional deficit.

A useful assessment separates the layers

Ask about collection volume, capture performance, cartridge recovery, blanks, calibration, analyte separation and repeat analysis. Then ask whether a separate study validates the proposed behavioral interpretation in the relevant population.

This paper supports an analytical breath-testing workflow and documents actual post-smoking samples. It does not establish a universal breath detection window, a legal limit or an individual driving-impairment classifier. Those additional claims require their own evidence.

For context, see our discussion of THC concentrations and the separate question of impairment.

Primary research

Shaza Deeb and colleagues. Simultaneous analysis of Δ9-THC, Δ8-THC, CBD, and CBN in breath aerosols collected using cannabix technologies breath collection unit. Journal of Analytical Toxicology (2026). DOI: 10.1093/jat/bkag016.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Other Medications Changed THC/CBD Spray Exposure in Different Directions

The effect of another medication on THC/CBD exposure depends on the drug and the pathway involved. A human interaction study found lower cannabinoid exposure with rifampicin, higher exposure with ketoconazole, and no significant pharmacokinetic change with omeprazole under the tested conditions. Three separate crossover comparisons Stott and colleagues studied 36…

Spread the love

Read Article: Other Medications Changed THC/CBD Spray Exposure in Different Directions

An Intermediate CBD Stress Response Was Not a Significant Placebo Difference

A CBD group’s average response can fall between placebo patients and healthy controls without demonstrating a significant CBD-versus-placebo benefit. A study of social stress in people at clinical high risk of psychosis illustrates this statistical distinction. Stress hormones and subjective symptoms were separate endpoints Participants at clinical high risk received…

Spread the love

Read Article: An Intermediate CBD Stress Response Was Not a Significant Placebo Difference

Two-Dimensional Cannabis GC–MS Testing Needs Correctly Timed Transfer Windows

Adding a second chromatography column can improve cannabinoid separation while introducing a new failure point: the analyte must reach the second column during the correct transfer window. A plasma assay study showed why those windows require verification. More separation brought more timing requirements Karschner and colleagues developed two-dimensional gas chromatography–mass…

Spread the love

Read Article: Two-Dimensional Cannabis GC–MS Testing Needs Correctly Timed Transfer Windows

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us